Acute leukemia

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Retrieved on: 
Giovedì, Maggio 9, 2024
FDA, Investment, Risk, Destiny, IND, Autoimmune disease, Enrollment, Death, Hospital, GAAP, NK, GEJ, Multiple myeloma, CRS, HER2, Pharmacokinetics, Graft-versus-host disease, Food, Lupus, Data, ADR, BCL, Histology, Therapy, BCMA, Autoimmunity, Safety, Trastuzumab, Research, TRAC, Incidence, IPSC, Chronic lymphocytic leukemia, Acute leukemia, Investigational New Drug, Cancer, Cell, Cmax, Patient, Gene, Society, B-cell lymphoma, BCM, Cytokine release syndrome, Immune system, SLE, Vaccine

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today reported business highlights and financial results for the first quarter ended March 31, 2024.

Key Points: 
  • The patient was discharged after a three-day hospital stay without any notable adverse events.
  • The Company will conduct a conference call today, Thursday, May 9, 2024 at 5:00 p.m.
  • ET to review financial and operating results for the quarter and full year ended March 31, 2024.
  • The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.fatetherapeutics.com.

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Retrieved on: 
Giovedì, Maggio 9, 2024
CD33, Cancer, Gene expression, Cell, Cranial cavity, Myelodysplastic syndrome, DRI, EHA, Survival, Temozolomide, Research and development, Canadian Aviation Regulations, GBM, AML, Leukemia, IND, ASCO, CD123, Patient, Gene, CML, Society, Acute myeloid leukemia, AACR, Annual general meeting, MDS, Acute leukemia, Pharmaceutical industry

NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results for the first quarter ended March 31, 2024 and recent corporate highlights.

Key Points: 
  • (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results for the first quarter ended March 31, 2024 and recent corporate highlights.
  • “We continued to make significant progress advancing our gamma-delta T cell programs in the first quarter of 2024,” said William Ho, CEO and co-founder of IN8bio.
  • INB-100: Report updated interim results from the ongoing Phase 1 investigator-sponsored trial at the 2024 EHA Annual Meeting, held June 13-16 in Madrid, Spain.
  • INB-200: Report interim Phase 1 long-term follow up results in GBM at multiple medical meetings in 2024 including at the 2024 ASCO Annual Meeting.

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

Retrieved on: 
Martedì, Aprile 16, 2024
Patient, Cancer, T-ALL, MRD, HLA, Collection, Trial of the century, HCT, AML, IND, Blood, Syndrome, Acute myeloid leukemia, Acute leukemia, Neoplasm, TCR, Therapy, MDS, ALL, Medical imaging

WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today provided an update on its solid tumor and heme malignancies clinical programs.

Key Points: 
  • “We continue to make meaningful progress across both our solid tumor and heme malignancies Phase 1 clinical programs.
  • This should allow for rapid enrollment into the treatment protocol over the course of the year,” said Gavin MacBeath, Ph.D., Chief Executive Officer.
  • Phase 1 solid tumor clinical study has been initiated; first three patients expected to be dosed in early May 2024.
  • Completion of Phase 1 enrollment and reporting of one-year clinical and translational data on initial patients is anticipated in the second half of 2024.

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Retrieved on: 
Giovedì, Aprile 11, 2024
Patient, BCR, Safety, MMR, TKI, CML, Caregiver, Second generation, Therapy, Acute leukemia, Pharmaceutical industry

BOULDER, Colo., April 11, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced positive proof of concept data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) who are relapsed, refractory, or intolerant to available tyrosine kinase inhibitors (TKIs) (NCT05304377).

Key Points: 
  • "Similar to our experience with previous successful Phase 1 trials in CML, ELVN-001 looks promising.
  • The preliminary data support that ELVN-001 is a potent and highly selective BCR::ABL1 inhibitor that has activity in heavily pre-treated patients, including post-asciminib patients."
  • “We are thrilled with ELVN-001’s initial Phase 1 data in heavily pre-treated patients with CML,” said Sam Kintz, Co-founder and Chief Executive Officer of Enliven.
  • The discussion will cover details of ELVN-001’s Phase 1 initial proof of concept data, the evolving treatment paradigm in CML, and how ELVN-001 could fit into the CML landscape.

Orphan designation: Ziftomenib Treatment of acute myeloid leukaemia, 12/01/2024 Positive

Retrieved on: 
Giovedì, Aprile 18, 2024
Patient, Committee, EMA, IRIS, COMP, European Commission, Marketing, D04, Acute leukemia, Medicine, Pharmaceutical industry

Overview

Key Points: 
  • Overview
    This medicine was designated as an orphan medicine for the treatment of acute myeloid leukaemia on 12 January 2024.
  • Orphan designation does not mean the medicine is available or authorised for use.
  • All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Orphan designation: cusatuzumab Treatment of acute myeloid leukaemia, 22/04/2020 Positive

Retrieved on: 
Giovedì, Aprile 18, 2024
Eurostat, Diagnosis, Civil service commission, Clinical research, Health, B cell, Growth, Cell, Bone marrow, Infection, AML, Disease, Patient, Committee, Knowledge, Regulation, CD70, Cancer, EMA, IRIS, Business park, Acute myeloid leukemia, European, COMP, European Commission, Blood, Azacitidine, Safety, Haematopoietic system, Marketing, Acute leukemia, Medicine, Pharmaceutical industry

Orphan designation: cusatuzumab Treatment of acute myeloid leukaemia, 22/04/2020 Positive

Key Points: 


Orphan designation: cusatuzumab Treatment of acute myeloid leukaemia, 22/04/2020 Positive

EQS-News: ActiTrexx treats first patient with novel regulatory T cell therapy against Graft-versus-Host Disease

Retrieved on: 
Mercoledì, Aprile 10, 2024
Cell, Bone marrow, Disease, Transplant, Risk, Clinic, Patient, Gastrointestinal tract, Mortality, Haematopoietic system, Leukemia, Quality of life, Graft-versus-host disease, Clinical trial, Skin, Safety, CSO, Liver, Acute leukemia, Vaccine

GvHD is a severe and potentially life-threatening complication that can arise after an allogeneic haematopoietic stem cell transplantation and affects about 50 % of recipients.

Key Points: 
  • GvHD is a severe and potentially life-threatening complication that can arise after an allogeneic haematopoietic stem cell transplantation and affects about 50 % of recipients.
  • GvHD occurs when the stem cell donor’s T cells attack the patient’s tissues, leading to a range of symptoms that can affect the skin, gastrointestinal tract, and liver.
  • Prof. Dr. Andrea Tüttenberg, CEO of ActiTrexx, said: “GvHD can lead to life-long symptoms for the patient and is a major cause for the high mortality rate of blood stem cell transplantation.
  • Ten patients who have recently received a blood stem cell transplantation as treatment for leukemia will receive a single treatment with Actileucel.

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

Retrieved on: 
Martedì, Aprile 9, 2024
Acute leukemia, Canadian Aviation Regulations, Cell, CD33, AML, Patient, Tissue, CML, Acute myeloid leukemia, Leukemia, Death, AACR, Neoplasm, Cancer, Safety, CD123, Antigen, Vaccine

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced new preclinical data from its non-signaling gamma-delta T cell based Chimeric Antigen Receptor-T cell (nsCAR) platform, known as INB-300, that demonstrated improved selectivity to target leukemia cells while preserving healthy ones. The data support the potential for nsCAR to have a wider therapeutic window and to be used to prevent on-target off-tumor killing of healthy tissue that may express the CAR-T target. The data was presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024 on April 9, 2024.

Key Points: 
  • The data was presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024 on April 9, 2024.
  • IN8bio's nsCAR platform is based on the natural ability of gamma-delta T cells to distinguish between healthy and malignant tissue.
  • Approved CAR-T therapies have shown remarkable efficacy against B cell malignancies, offering hope to patients with limited treatment options.
  • “These results can potentially improve INB-300, as we advance towards IND enabling studies of our next-generation gamma-delta T cell therapies to treat cancers.”

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

Retrieved on: 
Venerdì, Aprile 5, 2024
IOV, Tao, Medicine, Savolitinib, VEGFR, Immunotherapy, Patient, MMAE, ERK, Relapse, Neoplasm, University, Huachung University, Cisplatin, Lymphoid leukemia, Lymphoma, Chongqing Medical University, Cholangiocarcinoma, Tyrosine-protein kinase SYK, Classification, Efficacy, MET, ADC, Cardiotoxicity, Nanjing Medical University, Non-receptor tyrosine kinase, Safety, Ferroptosis, Macrophage, Pancreatic cancer, Dual role, National Taiwan University Hospital, GPR34, Oncology, Guangzhou Medical University, MD Anderson Cancer Center, Daratumumab, HCM, NPM1, MLL, 301 Hospital, Acute leukemia, Pharmaceutical industry

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.

Key Points: 
  • HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.
  • Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of certain types of acute leukemia.
  • Compared with five other menin inhibitors in clinical development, HMPL-506 showed the stronger inhibitory potency in MLL-rearranged and NPM1 mutant leukemia cell line models.
  • Furthermore, HMPL-506 in combination with azacytidine, venetoclax or gilteritinib synergistically improved the anti-tumor effect against MLL-rearranged leukemias both in vitro and in vivo.

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

Retrieved on: 
Giovedì, Marzo 28, 2024
Patient, BCR, Acute leukemia, CML, Therapy, ATP, Pharmaceutical industry

ET to discuss initial proof of concept data on ELVN-001 and the evolving chronic myeloid leukemia (CML) landscape.

Key Points: 
  • ET to discuss initial proof of concept data on ELVN-001 and the evolving chronic myeloid leukemia (CML) landscape.
  • ELVN-001 is a highly selective, small molecule kinase inhibitor designed to specifically target the ATP-pocket of the BCR-ABL gene fusion, the oncogenic driver for patients with CML.
  • The discussion will cover ELVN-001’s Phase 1a initial proof of concept data, the evolving treatment paradigm in CML, and how ELVN-001 could fit into the CML landscape.
  • The event will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at https://ir.enliventherapeutics.com/ .